Hematide

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) today announced the promotion of Cynthia Smith to vice president, market access and commercial development. Ms. Smith, who has 15 years of experience in healthcare market access strategies, joined Affymax in October 2008 as executive director, publ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) today announced that it will webcast an analyst briefing on Tuesday, January 10 at 7:15 a.m. PT. During the event, Affymax management will provide a general business update including a discussion of the peginesatide development program. ...

OSAKA, Japan & PALO ALTO, Calif.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda has decided not to commercialize peginesatide in Japan. Peginesatide is an investigational therapy for use in the treatment of patients with anemia due t...

SILVER SPRING, Md. & OSAKA, Japan--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, with 1 abstention, that peginesatide demonstrated a favor...

PHILADELPHIA--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced results from additional analyses of the EMERALD Phase 3 studies that evaluated the investigational agent peginesatide in dialysis patients with anemia due to chronic kidney ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2011. The net loss for the third quarter of 2011 was $9.8 million compared to a net loss of $12.0 million for the third quarter of 2010. Affymax reco...

Ends Ongoing Litigation and Legal Expenses PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) today announced that it has reached a global settlement agreement with Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) and certain of its affiliated companies to end the ...

Oncologic Drugs Advisory Committee Meeting Scheduled for December 7, 2011 PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Applicatio...

PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide (formerly known as Hematide™) have been accepted for presentation at the American Society...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) today announced the company's participation at the following investor conferences during the month of September.   ● ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide (formerly known as Hematide™) New Drug App...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), A...

Reaffirms Guidance for 2011 PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the second quarter ended June 30, 2011. The net loss for the second quarter of 2011 was $12.5 million compared to net income of $17.3 million for the sec...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (NASDAQ:AFFY) today announced the promotion of Krishna Polu, M.D. to vice president, Clinical Development. Dr. Polu, a nephrologist, joined Affymax in 2009 as executive director, Clinical Development. "I am pleased to recognize Krishna's ...

PALO ALTO, Calif. & DEERFIELD, Ill.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for peginesatide (formerly known as Hematide™) f...

PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)-- Affymax, Inc. (NASDAQ:AFFY) and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational agent peginesatide (formerly known a...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) today reported financial results for the first quarter ended March 31, 2011. The net loss for the first quarter of 2011 was $9.6 million compared to a net loss of $7.9 million for the first quarter of 2010. Affymax recogniz...

LAS VEGAS & OSAKA, Japan--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502, "Takeda"), today announced results of additional analyses from two Phase 3 studies (EMERALD 1 and 2) of the investigational agent, peginesatide (formerly known as Hematide™) in chron...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) today announced the company's participation at the following investor conferences during the month of May. Deutsche Bank Securities 36th Annual Health Care ConferenceWednesday, May 4, 201112:55 p.m. Eastern Time ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Affymax, Inc. (Nasdaq: AFFY) today announced that Andrew T. Blair, M.D., a nephrologist with over a decade of experience leading development strategy, regulatory and medical affairs for early- to late-stage renal disease programs, has joined the company as vice president of Me...